| abstract |
REFERRING TO THE SOLVATE OF 3- (1- {3- [5- (1-METHYL-PIPERIDIN-4-ILMETOXI) -PYRIMIDIN-2-IL] -BENZYL} -6-OXO-1,6-DIHIDRO-PIRAZIN -3-IL) -BENZONITRILE AND ITS CRYSTALLINE FORMS WITH XRD PEAKS (IN 2 THETA USING RADIATION Cu-K ALPHA1 +/- 0.1º): a) FORM A1 WITH XRD PEAKS OF 4.4º, 15.9º AND 22, 7º, b) H1 SHAPE WITH XRD PEAKS OF 5.9º, 16.0º AND 23.4º, c) NF3 SHAPE WITH XRD PEAKS OF 9.9º, 15.7º AND 24.1º, d) NF6 SHAPE WITH XRD PEAKS OF 16.8º, 18.2º AND 25.8º, e) FORM NF4 WITH XRD PEAKS OF 6.0º, 15.7º AND 24.7º, f) FORM NF2 WITH XRD PEAKS OF 5.2º, 23.8º AND 24, 5th. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCESS |